Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W ELECTROLYTES.
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 5.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and metabolic processes; dextrose supplies glucose for energy; electrolytes maintain fluid and electrolyte balance.
TRAVASOL 5.5% W/ ELECTROLYTES is a parenteral nutritional solution providing amino acids and electrolytes. Amino acids serve as substrates for protein synthesis, while electrolytes maintain osmotic balance and support cellular functions. The solution bypasses gastrointestinal absorption, directly entering the bloodstream.
Intravenous infusion: 500 mL/day initially, titrate to provide 1.5-2 g/kg/day of amino acids and 25-50 g/kg/day of dextrose; monitor electrolytes.
Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.
None Documented
None Documented
Amino acids: 0.5-2 hours (rapid clearance); dextrose: ~1-2 hours (insulin-dependent). Clinical context: Continuous IV infusion maintains steady state.
2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Renal (amino acids: ~80% reabsorbed, excess excreted unchanged; dextrose: primarily metabolized, small fraction excreted renally <5%; electrolytes: renal excretion proportional to intake and plasma levels).
Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution